Cernea S, Onișor D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(2): 286-309 [PMID: 36687124 DOI: 10.3748/wjg.v29.i2.286]
Corresponding Author of This Article
Simona Cernea, MD, PhD, Associate Professor, Department M3/Internal Medicine I, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu st., Târgu Mureş 540139, Romania. simonacernea@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2023; 29(2): 286-309 Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.286
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
Simona Cernea, Danusia Onișor
Simona Cernea, Department M3/Internal Medicine I, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureş 540139, Romania
Simona Cernea, Diabetes, Nutrition and Metabolic Diseases Outpatient Unit, Emergency County Clinical Hospital, Târgu Mureş 540136, Romania
Danusia Onișor, Department ME2/Internal Medicine VII, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureş, Târgu Mureş 540139, Romania
Danusia Onișor, Gastroenterology Department, Mureș County Clinical Hospital, Târgu Mureș 540072, Romania
Author contributions: Cernea S conceived and designed the review, researched the literature, wrote part of the manuscript, edited, created the figures, and critically revised the manuscript for important intellectual content; Onișor D researched the literature and contributed to the writing of the manuscript and final validation; Both authors approved the final version.
Conflict-of-interest statement: The authors declare having no conflicts of interest regarding this paper.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Simona Cernea, MD, PhD, Associate Professor, Department M3/Internal Medicine I, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu st., Târgu Mureş 540139, Romania. simonacernea@yahoo.com
Received: September 18, 2022 Peer-review started: September 18, 2022 First decision: October 19, 2022 Revised: November 6, 2022 Accepted: December 21, 2022 Article in press: December 21, 2022 Published online: January 14, 2023 Processing time: 109 Days and 6.6 Hours
Core Tip
Core Tip: Nonalcoholic fatty liver disease (NAFLD) is a public health problem, especially in developed countries. This condition, depending on certain associated risk factors, can ultimately lead to liver cirrhosis and hepatocellular carcinoma (HCC). Having the necessary tools and knowing the characteristics of patients in whom the disease progresses more quickly, effective monitoring programs can be developed. Primary prevention of NAFLD/nonalcoholic steatohepatitis (NASH)-associated HCC relies on controlling the main modifiable risk factors. Some pharmacological (e.g., metformin, statins, aspirin) and non-pharmacological interventions (weight loss, physical exercise, healthy diet, avoiding heavy drinking and smoking) might have protective effects. Herein, we emphasized the need for continued investigations to find the optimal methods for NAFLD/NASH-associated prevention.
